Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 8
2007 7
2008 6
2009 4
2010 7
2011 10
2012 13
2013 13
2014 10
2015 15
2016 18
2017 18
2018 17
2019 12
2020 20
2021 13
2022 4
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Shaw AT, et al. Among authors: costa db. N Engl J Med. 2014 Nov 20;371(21):1963-71. doi: 10.1056/NEJMoa1406766. Epub 2014 Sep 27. N Engl J Med. 2014. PMID: 25264305 Free PMC article. Clinical Trial.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA, Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK, Hammerman PS. Koyama S, et al. Among authors: costa db. Nat Commun. 2016 Feb 17;7:10501. doi: 10.1038/ncomms10501. Nat Commun. 2016. PMID: 26883990 Free PMC article.
Authors' Response.
Cheng MP, Marty FM, Costa DB, Awad MM. Cheng MP, et al. Among authors: costa db. J Thorac Oncol. 2018 Nov;13(11):e237. doi: 10.1016/j.jtho.2018.09.015. J Thorac Oncol. 2018. PMID: 30368420 Free article. No abstract available.
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, Jänne PA. Riely GJ, et al. Among authors: costa db. Cancer Discov. 2021 Jul;11(7):1688-1699. doi: 10.1158/2159-8290.CD-20-1598. Epub 2021 Feb 25. Cancer Discov. 2021. PMID: 33632775 Free PMC article. Clinical Trial.
TIP60 is required for tumorigenesis in non-small cell lung cancer.
Shibahara D, Akanuma N, Kobayashi IS, Heo E, Ando M, Fujii M, Jiang F, Prin PN, Pan G, Wong KK, Costa DB, Bararia D, Tenen DG, Watanabe H, Kobayashi SS. Shibahara D, et al. Among authors: costa db. Cancer Sci. 2023 Jun;114(6):2400-2413. doi: 10.1111/cas.15785. Epub 2023 Apr 18. Cancer Sci. 2023. PMID: 36916958 Free PMC article.
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Oxnard GR, et al. Among authors: costa db. JAMA Oncol. 2018 Nov 1;4(11):1527-1534. doi: 10.1001/jamaoncol.2018.2969. JAMA Oncol. 2018. PMID: 30073261 Free PMC article.
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Yasuda H, et al. Among authors: costa db. Sci Transl Med. 2013 Dec 18;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. Sci Transl Med. 2013. PMID: 24353160 Free PMC article.
Scientific Advances in Thoracic Oncology 2016.
Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Soo RA, et al. Among authors: costa db. J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. J Thorac Oncol. 2017. PMID: 28579481 Free article. Review.
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, Costa DB. Sentana-Lledo D, et al. Among authors: costa db. Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5. Transl Lung Cancer Res. 2023. PMID: 37577308 Free PMC article. Review.
199 results